ArticleClinical pharmacology in drug development2022

Single-Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.

Ramesh Boinpally et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.